ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
21 Oct, 2021
– Teon Therapeutics completed a $30m Series A financing.
– The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives.
– All existing investors also participated in the financing round including Northern Light Venture Capital, Kaitai Capital and Oriental Fortune Capital.
– The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.